These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19085437)

  • 1. Cannabis using schizophrenia patients treated with atypical neuroleptics: do their symptoms differ from those of cannabis abstainers?
    Schaub M; Fanghaenel K; Senn C; Stohler R
    Subst Use Misuse; 2008 Dec; 43(14):2045-52. PubMed ID: 19085437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopharmacotherapy and remission of patients with schizophrenia.
    Degmecić D; Pozgain I; Filaković P; Dodig-Curković K; Mihanović M
    Coll Antropol; 2009 Jun; 33(2):547-51. PubMed ID: 19662777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls.
    Schaub M; Fanghaenel K; Stohler R
    Aust N Z J Psychiatry; 2008 Dec; 42(12):1060-5. PubMed ID: 19016094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of drug use and dependence between blunt smokers and other cannabis users.
    Timberlake DS
    Subst Use Misuse; 2009; 44(3):401-15. PubMed ID: 19212929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
    Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
    Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.
    Karow A; Schnedler D; Naber D
    Pharmacopsychiatry; 2006 Mar; 39(2):47-51. PubMed ID: 16555164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
    Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
    Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid relationships in former cannabis users with schizophrenia.
    Monterrubio S; Solowij N; Meyer BJ; Turner N
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):280-5. PubMed ID: 16236415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
    Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
    Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis.
    van Rossum I; Boomsma M; Tenback D; Reed C; van Os J;
    J Nerv Ment Dis; 2009 Jan; 197(1):35-40. PubMed ID: 19155808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
    Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
    Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial.
    Clausen L; Hjorthøj CR; Thorup A; Jeppesen P; Petersen L; Bertelsen M; Nordentoft M
    Psychol Med; 2014 Jan; 44(1):117-26. PubMed ID: 23590927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia].
    Lisoprawski A
    Sem Hop; 1983 Jun; 59(25):1925-7. PubMed ID: 6136096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Validation of the Temporal Experience of Pleasure Scale (TEPS) in a French-speaking environment].
    Favrod J; Ernst F; Giuliani F; Bonsack C
    Encephale; 2009 Jun; 35(3):241-8. PubMed ID: 19540410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia.
    Hamera E; Schneider JK; Deviney S
    J Nerv Ment Dis; 1995 Sep; 183(9):559-65. PubMed ID: 7561817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.